miR-155-5p Facilitates the Growth of Lobaplatin-Treated Gastric Cancer Cells

Abstract

Introduction: MicroRNAs (miRNAs) play vital roles in tumorigenesis and metastasis. The role of miR-155-5p in various cancers has been widely reported;However, its role in gastric cancer (GC) remains unknown. The aim of the present study was to investigate the role of miR-155-5p in GC pathogenesis and drug resistance. Methods: The miRNA profiles of GC were downloaded from the University of California Santa Cruz Xena database, and miR-155-5p levels in normal and GC tissues were analyzed. Adjacent and cancer tissues were collected from patients with GC. Real-time quantitative polymerase chain reaction (RT-qPCR) was used to analyze miR-155-5p levels in GC tissues and cell lines. Then, the NCI-N87 (human GC cells NCI-N87) cells were divided into four groups: Control, miR-155-5p-OE (overexpression), LP (lobaplatin), and miR-155-5p-OE+LP groups. The cells in the miR-155-5p-OE, and miR-155-5p-OE+LP groups were both transfected with miR-155-5p mimics, and then the cells in the miR-155-5p-OE+LP group were treated with 5 µg/mL lobaplatin. The cells in the LP group were only treated with lobaplatin, while the cells in the control group were without treatments. After culture, Transwell and cell counting kit-8 assays were used to assess the migratory and invasive capacities and viability, respectively, of lobaplatin-treated GC cells. Results: Bioinformatic analysis and RT-qPCR results showed that miR-155-5p was highly abundant in GC tissues and cell lines. Enrichment of miR-155-5p facilitated the growth of NCI-N87 cells. Additionally, lobaplatin treatment significantly decreased miR-155-5p levels in NCI-N87 cells and inhibited the viability and migratory and invasive capacities, whereas miR-155-5p enrichment rescued the GC cells from the inhibitory effects of lobaplatin treatment. Conclusions: Our results revealed that miR-155-5p promotes the growth of NCI-N87 cells, and its enrichment rescues NCI-N87 cells from the inhibitory effects of lobaplatin treatment. Thus, miR-155-5p may be a potential molecular target for the treatment of GC.